BALAMINES · Balaji Amines Ltd · Chemical Manufacturing
BALAMINES · Balaji Amines Ltd · Chemical Manufacturing
As of 05 Nov close
52-week range
31.8% below 52-week high
52-week range: as of 05 Nov 2026 close.
Price chartDaily closes on the stock page.
Weighted combination of 8 measured readings. Not a probability, a rating or a forecast.
Full signal detail →Fundamentals as of 15 Sep 2026 · the company's own latest record is 52 days old
Revenue (latest Q)
₹456 Cr
Revenue YoY
PAT YoY
+97.2%
Operating margin
Revenue, last 8 quarters
P/E (TTM)
P/B
3.5
P/S (TTM)
4.8
Sector P/E
20.6
Dividend yield
+0.5%
| Company | P/E | P/B | Net margin | ROE | D/E | Div. yield |
|---|---|---|---|---|---|---|
| BALAMINES (this stock) | 32.4 | 3.5 | +13.4% | +10.3% | 0.07 | +0.5% |
| Asian Paints | 53 | 11.1 | +12.8% | +22.3% | 0.18 | +1.1% |
| Solar Industries India | 99.6 | 26.6 | +17.6% | +31.4% | 13.68 | +0.1% |
| Pidilite Industries | 61.3 | 19.4 | +17.2% | +24.4% | 0.04 | +0.7% |
Promoter
stable
FII
rising 1q
MF
0.12% (0.00pp)
stable
Insider trades
No insider trades in the last 12 months.
Bulk/block deals
No bulk/block deals in the last 12 months.
News timeline
- loweconomictimes.indiatimes.com· 27 Jul 2026, 12:24 pmQ1 Results today: Coal India, Tata Power, BEL, Coforge, among 68 companies to announce earnings
Concalls & investor presentations
AI-generatedKey takeaway: Balaji Amines Limited's investor presentation for Q2 and H1 FY27 highlights strong financial performance, with consolidated total revenue rising 36% year-on-year to ₹472 crore, EBITDA increasing 58% to ₹106 crore, and PAT growing 82% to ₹67 crore. For H1 FY27, consolidated PAT nearly doubled to ₹146 crore. Despite challenges like raw material availability and supply chain delays, the company maintained resilient revenue growth, with standalone volumes up 11% over Q1. Key operational developments include the commercial production of Acetonitrile at an upgraded facility and the commencement of DME road tanker valves with PESO approval. The company is advancing its expansion roadmap, with BSCL's Unit-I brownfield expansion on track for end-FY27 and Unit-II HCN, NaCN, and EDTA projects targeted for Q4 FY27. Management emphasized confidence in driving sustainable growth and long-term shareholder value through disciplined execution and a visible expansion plan. The presentation also outlined the company's diversified product portfolio, strategic focus on import substitution, and strong balance sheet with ₹2,262 crore net worth. The company's standalone business remains debt-free, and it has a robust manufacturing base with 4,02,600 MTPA installed capacity. The presentation included historical financial performance, consistent dividend payouts, and ESG initiatives, along with details on the company's global export presence across 50+ countries.
The presentation emphasizes strong financial growth, successful operational developments, and confidence in future expansion, reflecting a positive tone.
Sourced from an exchange-filed presentation, dated 04 Nov 2026. Summary is RedixFi-generated and distinct from investment advice.
Key takeaway: Balaji Amines Limited's investor presentation for Q1 FY27 highlighted a strong operational and financial performance, with resilient margins supported by improving demand across key industries. Management reported the commissioning of India's first commercial-scale 100,000 TPA Dimethyl Ether plant, marking a significant milestone in diversifying into new-age chemicals and alternate fuels. The presentation detailed financial metrics, showing a year-on-year revenue increase of 25.73% to INR 461 Cr and a 110.19% rise in profit after tax to INR 78 Cr. Management noted that expansion projects for N-Methyl Morpholine and Acetonitrile are on track for commissioning by the end of the financial year. The company emphasized its commitment to import substitution and sustainable growth, backed by a healthy order pipeline and disciplined execution. The presentation also outlined the company's diversified product portfolio and strategic initiatives aimed at enhancing operational efficiency and market presence.
Management emphasized strong performance and growth initiatives.
Sourced from an exchange-filed presentation, dated 29 Jul 2026. Summary is RedixFi-generated and distinct from investment advice.
Key takeaway: Balaji Amines Limited held its Q4 FY26 Earnings Conference Call on May 18, 2026, where management reported a year-on-year revenue growth of approximately 12%, reaching INR403 crores for the quarter. The consolidated EBITDA increased to INR102 crores, with an EBITDA margin of 25%, up from 19% in the previous year. Profit after tax for the quarter was INR65 crores, compared to INR40 crores in Q4 FY25. Management highlighted the company's zero-debt status and strong financial discipline. They discussed ongoing expansion projects, including a DME plant and specialty chemicals, which are anticipated to enhance the product portfolio and support future growth. Management noted stable demand across key segments and emphasized the importance of their integrated manufacturing model. They guided toward a volume growth of 20% to 30% in the upcoming financial year, driven by new product launches and improved capacity utilization. The call concluded with management expressing confidence in the company's strategic direction and operational stability.
Management emphasized strong financial performance and ongoing growth initiatives.
Sourced from an exchange-filed transcript, dated 23 May 2026. Summary is RedixFi-generated and distinct from investment advice.
Key takeaway: On May 15, 2026, Balaji Amines Limited submitted an investor presentation detailing its Q4FY26 financial results. The presentation reported a consolidated revenue of ₹403 crore for Q4FY26, up from ₹336 crore in Q3FY26, with total volumes reaching 27,341 MT. EBITDA for the quarter was ₹102 crore, compared to ₹62 crore in Q3FY26, resulting in an EBITDA margin of 25%. PAT was reported at ₹65 crore, significantly higher than ₹31 crore in Q3FY26. The company highlighted ongoing projects, including a Dimethyl Ether plant and expansions in Balaji Speciality Chemicals, with a total investment of ₹750 crore. Management emphasized the company's zero-debt status and its leadership in the methylamines market. The presentation also outlined the company's commitment to sustainability through a solar power initiative and its strategic focus on high-value derivatives and specialty chemicals.
Management highlighted strong financial performance and ongoing strategic projects.
Sourced from an exchange-filed presentation, dated 15 May 2026. Summary is RedixFi-generated and distinct from investment advice.
AI Summary of Annual Report
AI-generatedBalaji Amines Limited (BALAMINES) reported FY2021-22 results with a focus on expanding production capacity for key chemicals like methylamines and DMF, aiming to strengthen its market position. The company faces ongoing disputes with tax authorities, with disputed income tax demands totaling ₹296.46 lakhs, partially covered by refunds. No major regulatory actions or defaults were noted, and the company maintains compliance with governance standards. It also emphasized corporate social responsibility, spending ₹425.02 lakhs on eligible projects.
- FY2021-22 saw plans to expand production capacity for N-Butylamine, Acetonitrile, Methylamine, and DMF, enhancing global market reach.
- Disputed income tax demands of ₹296.46 lakhs remain pending, with ₹87.38 lakhs deposited and the balance adjusted against refunds.
- No defaults in loan repayments or regulatory penalties were reported, and the company maintains compliance with governance standards.
- Corporate Social Responsibility (CSR) expenditure amounted to ₹425.02 lakhs, including ₹105.13 lakhs for an electrical cremation furnace project.
- The company has no fixed deposits, and no significant orders from regulators impacting its going-concern status were noted.
Key takeaway: Balaji Amines Limited is expanding its production capacity and focusing on CSR, but faces unresolved tax disputes that could impact its financial position.
The following annual report excerpts provide qualitative strategic context. Do not treat any specific financial figures in these excerpts as authoritative — they may be incorrectly labeled due to PDF table extraction limitations. For precise financial data, refer to the structured fundamentals data above.
Governance disclosures
AI-generatedNeeds attention
Auditor Qualification (1 item); Regulatory Action (2 items)
Items of these kinds are disclosed in the filings. This is a count of disclosed items. It is not a finding about the company and its cause has not been independently established.
Auditor Qualification
1 occurrenceOlder (3+ years ago)
The auditor mentions a disputed tax demand related to Income Tax Assessments for 5 years (Assessment years 2013-14, 2014-15, 2015-16, 2016-17, and 2017-18). This indicates a potential issue with the company's tax compliance.
Regulatory Action
2 occurrencesEarlier (1-3 years ago)
The company and its officials were fined by the Office of Joint Director General of Foreign Trade, Pune for submitting inaccurate GST invoices of exempted material. The company has submitted a review application.
The company received notices from Stock Exchanges under SEBI regulations and paid necessary fines.
Routine disclosures
Internal Control Weakness
2 occurrencesRecent (last 12 months)
The auditor identified a significant deficiency in internal control related to the appropriateness of capitalisation of costs under Ind AS 16, specifically regarding the capitalisation of Rs 45.07 Crores for a new solar plant and Rs 22.88 Crores for the expansion of Unit IV.
Earlier (1-3 years ago)
The auditor identified a risk of improper management override of controls, leading to potential material misstatements due to error or fraud that may not be detected.
Contingent Liability
4 occurrencesRecent (last 12 months)
The company has contingent liabilities including claims not acknowledged as debts, income tax, and guarantees as of March 31, 2026 and 2025.
Earlier (1-3 years ago)
The company has contingent liabilities related to income tax demands for assessment years 2013-14 to 2020-21, with ₹546.54 lakh paid under protest, and pending disputes before the Commissioner of Income Tax (Appeals). Additionally, there is a custom duty liability due to incorrect application of concessional rates on ethanol.
The company has contingent liabilities in the form of claims against it not acknowledged as of March 31, 2024.
Older (3+ years ago)
The company has disputed demands under the Income Tax Act for various assessment years, amounting to a total of ₹17.60 Lakhs, ₹231.08 Lakhs, ₹9.25 Lakhs, and ₹29.31 Lakhs.
Related-Party Transaction
3 occurrencesRecent (last 12 months)
The company has disclosed transactions with related parties, including enterprises where Key Management Personnel (KMP) have significant influence or control, such as MVL Medisynth Private Limited, SVS Sourcings Private Limited, and APR Holdings and Investments LLP, along with compensation to KMP members.
Older (3+ years ago)
The company has disclosed related party transactions involving key management personnel (KMP) and their associated enterprises, including subsidiaries and entities where KMP have significant influence or control.
The company has a related-party transaction with Balaji Speciality Chemicals Limited, involving an unsecured loan of ₹20 crore, interest receipt of ₹5.43 crore, and a balance outstanding of ₹66 crore as of the balance sheet date.
Promoter Share Pledge
1 occurrenceRecent (last 12 months)
14.42% of promoter holding pledged (quarter 2026-Q3 as of 2026-07-18).